文献速递胸部肿瘤放疗放疗物理与技术

立体定向体部放疗治疗肺尖部肺癌后臂丛神经病变:剂量学分析与初步临床结果

Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes.
PubMed 文献 · Adv Radiat Oncol · 2017-10-12

该研究纳入75例接受SBRT的T1-T3N0非小细胞肺癌患者,其中31例肺尖部肿瘤符合剂量学分析标准。中位随访17个月,臂丛神经病变发生率为0%,但臂丛神经受照剂量存在显著差异。

要点

  • 肺尖部肿瘤SBRT时臂丛神经受照剂量存在显著个体差异。
  • 本组病例中位随访17个月,未观察到臂丛神经病变症状。
  • 需进一步关注臂丛神经剂量与临床后果的关系。

核心结论

  • 肺尖部肺癌SBRT时臂丛神经剂量变异大,但本组病例神经症状发生率为0%。

研究设计与样本

  • 回顾性分析2009年6月至2017年2月连续75例接受SBRT的T1-T3N0非小细胞肺癌患者,其中31例肺尖部肿瘤符合剂量学分析条件。

主要发现

  • 31例肺尖部肿瘤患者中位年龄73岁,中位PTV 26.5 cc,臂丛神经中位最大剂量15.8 Gy,中位分次最大剂量3.4 Gy,中位随访17个月臂丛神经病变发生率为0%。

关键数值与推荐

  • 臂丛神经中位最大剂量15.8 Gy(范围1.7-66.5 Gy),中位分次最大剂量3.4 Gy(范围0.6-14.7 Gy),V22(3-4分次)中位0.0 cc(范围0-0.9 cc),V30(5分次)中位0.06 cc(范围0-2.5 cc),BED3中位31.5 Gy(范围3.3-133.1 Gy)。

临床怎么用

  • 肺尖部肺癌SBRT时应依据RTOG图谱勾画臂丛神经并关注其受照剂量,尽管本组神经症状发生率为0%,仍需个体化评估。

局限性

  • 样本量较小(31例),随访时间较短,臂丛神经病变发生率低,需更大样本和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment of apical lung tumors with stereotactic body radiation therapy (SBRT) is challenging due to the proximity of the brachial plexus and the concern for nerve damage. METHODS AND MATERIALS: Between June 2009 and February 2017, a total of 75 consecutive patients underwent SBRT for T1-T3N0 non-small cell lung cancer involving the upper lobe of the lung. All patients were treated with 4-dimensional computed tomography (CT)-based image guided SBRT to a dose of 40 to 60 Gy in 3 to 5 fractions. For dosimetric analysis, only apical tumors as defined by the location of the tumor epicenter superior to the aortic arch were included. The anatomical brachial plexus was delineated using the Radiation Therapy Oncology Group atlas. RESULTS: Thirty-one patients with 31 apical lung tumors satisfied the anatomical criteria for inclusion. The median age was 73 years (range, 58-89). The median planning target volume was 26.5 cc (range, 8.2-81.4 cc). The median brachial plexus, brachial plexus maximum dose (Dmax), Dmax per fraction, V22 (cc, 3-4 fractions), V30 (cc, 5 fractions), and biologically effective dose 3 Gy were 15.8 Gy (range, 1.7-66.5 Gy), 3.4 Gy (range, 0.6-14.7 Gy), 0.0 cc (range, 0-0.9 cc), 0.06 cc (range, 0-2.5 cc), and 31.5 Gy (range, 3.3-133.1 Gy), respectively. At a median follow-up of 17 months, the observed incidence of brachial plexopathy was 0%. CONCLUSIONS: There is significant variation in dose to the brachial plexus for patients treated with SBRT for apical lung tumors. Although the incidence of neuropathic symptoms in this series was zero, further attention should be focused on the clinical implications of these findings.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sood SS, McClinton C, Badkul R, et al. Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes. Adv Radiat Oncol. 2017. PMID: 29556585. doi:10.1016/j.adro.2017.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。